SCN8A and Its Related Epileptic Phenotypes

Abstract

Sodium channelopathies are among the most common single-gene causes of epilepsy and have been considered model disorders for the study of genetic epilepsies. Epilepsies due to SCN8A pathogenic variants can present with a broad range of phenotypes varying from a severe epileptic encephalopathy with multiple types of drug-resistant seizure to neurodevelopmental delay, mental retardation, and electroencephalogram (EEG) findings of multifocal spike and waves (mostly in the temporal/parietal/occipital areas). In rare cases, benign familial infantile seizures and developmental delay with/without ataxia have been reported. A first-level, specific SCN8A Sanger's sequencing, although available, is rarely performed because the clinical phenotype is not strictly characteristic and several overlaps with other genetic epilepsies may occur. Given its indistinctive phenotype, diagnosis is usually performed through a specific gene panel for epileptic encephalopathies, early epilepsies, or genetic epilepsy in general, or through whole exome sequencing (WES) and more rarely through whole genome sequencing (WGS). Mutations in SCN8A occur as an autosomal dominant trait. The great majority of individuals diagnosed with SCN8A epilepsy do not have an affected parent, because usually SCN8A patients do not reproduce, and mutations are inherited as a “de novo” trait. In rare cases, SCN8A mutations may be inherited in the setting of parental germline mosaicism. SCN8A-related epilepsies have not shown a clear genotype–phenotype correlation, the same variants have been described with different clinical expressivity and this could be due to other genetic factors or to interacting environmental factors. There is no standardized treatment for SCN8A-related epilepsy because of the rarity of the disease and the unavailability of specific, targeted drugs. Treatment is based mainly on antiepileptic drugs which include classic wide-spectrum drugs such as valproic acid, levetiracetam, and lamotrigine. Sodium-channel blockers (phenytoin, carbamazepine, oxcarbazepine, and lamotrigine) have shown appreciable results in terms of seizure reduction, in particular, in patients presenting gain-of-function mutations. Nowadays, new potentially transformative gene therapy treatment approaches are currently being explored, allowing in the next future, a precision-based treatment directed against the gene defect and protein alterations.

Keywords

SCN8A - sodium channel - benign familial infantile seizures - epileptic encephalopathy - movement disorders

Publikationsverlauf

Eingereicht: 01. September 2020

Angenommen: 27. Januar 2021

Artikel online veröffentlicht:
28. Mai 2021

• References

• 1 Veeramah KR, O'Brien JE, Meisler MH. et al. De novo pathogenic SCN8A mutation identified by whole-genome sequencing of a family quartet affected by infantile epileptic encephalopathy and SUDEP. Am J Hum Genet 2012; 90 (03) 502-510
• 2 de Kovel CG, Meisler MH, Brilstra EH. et al. Characterization of a de novo SCN8A mutation in a patient with epileptic encephalopathy. Epilepsy Res 2014; 108 (09) 1511-1518
• 3 Blanchard MG, Willemsen MH, Walker JB. et al. De novo gain-of-function and loss-of-function mutations of SCN8A in patients with intellectual disabilities and epilepsy. J Med Genet 2015; 52 (05) 330-337
• 4 Wagnon JL, Meisler MH. Recurrent and Non-Recurrent Mutations of SCN8A in Epileptic Encephalopathy. Front Neurol 2015; 6: 104
• 5 Lopez-Santiago LF, Yuan Y, Wagnon JL. et al. Neuronal hyperexcitability in a mouse model of SCN8A epileptic encephalopathy. Proc Natl Acad Sci U S A 2017; 114 (09) 2383-2388
• 6 Oliva M, Berkovic SF, Petrou S. Sodium channels and the neurobiology of epilepsy. Epilepsia 2012; 53 (11) 1849-1859
• 7 Brunklaus A, Du J, Steckler F. et al. Biological concepts in human sodium channel epilepsies and their relevance in clinical practice. Epilepsia 2020; 61 (03) 387-399
• 8 Battaglia D, Ricci D, Chieffo D, Guzzetta F. Outlining a core neuropsychological phenotype for Dravet syndrome. Epilepsy Res 2016; 120: 91-97
• 9 Pan Y, Cummins TR. Distinct functional alterations in SCN8A epilepsy mutant channels. J Physiol 2020; 598 (02) 381-401
• 10 Gertler TS, Carvill GL. SCN8A: when neurons are so excited, they just can't hide it. Epilepsy Curr 2019; 19 (04) 269-271
• 11 Meisler MH. SCN8A encephalopathy: mechanisms and models. Epilepsia 2019; 60 (Suppl. 03) S86-S91
• 12 Spampanato J, Escayg A, Meisler MH, Goldin AL. Functional effects of two voltage-gated sodium channel mutations that cause generalized epilepsy with febrile seizures plus type 2. J Neurosci 2001; 21 (19) 7481-7490
• 13 Rush AM, Dib-Hajj SD, Waxman SG. Electrophysiological properties of two axonal sodium channels, Nav1.2 and Nav1.6, expressed in mouse spinal sensory neurones. J Physiol 2005; 564 (Pt 3): 803-815
• 14 Maurice N, Tkatch T, Meisler M, Sprunger LK, Surmeier DJ. D1/D5 dopamine receptor activation differentially modulates rapidly inactivating and persistent sodium currents in prefrontal cortex pyramidal neurons. J Neurosci 2001; 21 (07) 2268-2277
• 15 Jarecki BW, Piekarz AD, Jackson II JO, Cummins TR. Human voltage-gated sodium channel mutations that cause inherited neuronal and muscle channelopathies increase resurgent sodium currents. J Clin Invest 2010; 120 (01) 369-378
• 16 Wagnon JL, Mencacci NE, Barker BS. et al. Partial loss-of-function of sodium channel SCN8A in familial isolated myoclonus. Hum Mutat 2018; 39 (07) 965-969
• 17 Wagnon JL, Barker BS, Ottolini M. et al. Loss-of-function variants of SCN8A in intellectual disability without seizures. Neurol Genet 2017; 3 (04) e170
• 18 Schreiber JM, Tochen L, Brown M. et al. A multi-disciplinary clinic for SCN8A-related epilepsy. Epilepsy Res 2020; 159: 106261
• 19 Gardella E, Møller RS. Phenotypic and genetic spectrum of SCN8A-related disorders, treatment options, and outcomes. Epilepsia 2019; 60 (Suppl. 03) S77-S85
• 20 Xiao Y, Xiong J, Mao D. et al. Early-onset epileptic encephalopathy with de novo SCN8A mutation. Epilepsy Res 2018; 139: 9-13
• 21 Larsen J, Carvill GL, Gardella E. et al; EuroEPINOMICS RES Consortium CRP. The phenotypic spectrum of SCN8A encephalopathy. Neurology 2015; 84 (05) 480-489
• 22 Meisler MH, Helman G, Hammer MF. et al. SCN8A encephalopathy: research progress and prospects. Epilepsia 2016; 57 (07) 1027-1035
• 23 Trivisano M, Pavia GC, Ferretti A, Fusco L, Vigevano F, Specchio N. Generalized tonic seizures with autonomic signs are the hallmark of SCN8A developmental and epileptic encephalopathy. Epilepsy Behav 2019; 96: 219-223
• 24 Pavone P, Striano P, Falsaperla R, Pavone L, Ruggieri M. Infantile spasms syndrome, West syndrome and related phenotypes: what we know in 2013. Brain Dev 2014; 36 (09) 739-751
• 25 Ruggieri M, Rizzo R, Pavone P, Baieli S, Sorge G, Happle R. Temporal triangular alopecia in association with mental retardation and epilepsy in a mother and daughter. Arch Dermatol 2000; 136 (03) 426-427
• 26 Ruggieri M, Iannetti P, Clementi M. et al. Neurofibromatosis type 1 and infantile spasms. Childs Nerv Syst 2009; 25 (02) 211-216
• 27 Kong W, Zhang Y, Gao Y. et al. SCN8A mutations in Chinese children with early onset epilepsy and intellectual disability. Epilepsia 2015; 56 (03) 431-438
• 28 Pavone P, Praticò AD, Pavone V. et al. Ataxia in children: early recognition and clinical evaluation. Ital J Pediatr 2017; 43 (01) 6
• 29 Gardella E, Marini C, Trivisano M. et al. The phenotype of SCN8A developmental and epileptic encephalopathy. Neurology 2018; 91 (12) e1112-e1124
• 30 Johannesen KM, Gardella E, Scheffer I. et al. Early mortality in SCN8A-related epilepsies. Epilepsy Res 2018; 143: 79-81
• 31 Pavone P, Praticò AD, Vitaliti G. et al. Hydranencephaly: cerebral spinal fluid instead of cerebral mantles. Ital J Pediatr 2014; 40: 79
• 32 Epifanio R, Zanotta N, Giorda R, Bardoni A, Zucca C. Novel epilepsy phenotype associated to a known SCN8A mutation. Seizure 2019; 67: 15-17
• 33 Gardella E, Becker F, Møller RS. et al. Benign infantile seizures and paroxysmal dyskinesia caused by an SCN8A mutation. Ann Neurol 2016; 79 (03) 428-436
• 34 Anand G, Collett-White F, Orsini A. et al. Autosomal dominant SCN8A mutation with an unusually mild phenotype. Eur J Paediatr Neurol 2016; 20 (05) 761-765
• 35 Johannesen KM, Gardella E, Encinas AC. et al. The spectrum of intermediate SCN8A-related epilepsy. Epilepsia 2019; 60 (05) 830-844
• 36 Musto E, Gardella E, Møller RS. Recent advances in treatment of epilepsy-related sodium channelopathies. Eur J Paediatr Neurol 2020; 24: 123-128
• 37 Atkin TA, Maher CM, Gerlach AC. et al. A comprehensive approach to identifying repurposed drugs to treat SCN8A epilepsy. Epilepsia 2018; 59 (04) 802-813
• 38 Lionetti E, Leonardi S, Franzonello C, Mancardi M, Ruggieri M, Catassi C. Gluten psychosis: confirmation of a new clinical entity. Nutrients 2015; 7 (07) 5532-5539
• 39 Rolvien T, Butscheidt S, Jeschke A. et al. Severe bone loss and multiple fractures in SCN8A-related epileptic encephalopathy. Bone 2017; 103: 136-143
• 40 Sorge G, Ruggieri M, Polizzi A, Scuderi A, Di Pietro M. SHORT syndrome: a new case with probable autosomal dominant inheritance. Am J Med Genet 1996; 61 (02) 178-181
• 41 Ranza E, Z'Graggen W, Lidgren M. et al. SCN8A heterozygous variants are associated with anoxic-epileptic seizures. Am J Med Genet A 2020; 182 (05) 1209-1216
• 42 Ruggieri M, Milone P, Pavone P. et al. Nevus vascularis mixtus (cutaneous vascular twin nevi) associated with intracranial vascular malformation of the Dyke-Davidoff-Masson type in two patients. Am J Med Genet A 2012; 158A (11) 2870-2880
• 43 Ruggieri M, Iannetti P, Pavone L. Delineation of a newly recognized neurocutaneous malformation syndrome with “cutis tricolor”. Am J Med Genet A 2003; 120A [phone]
• 44 Trudeau MM, Dalton JC, Day JW, Ranum LP, Meisler MH. Heterozygosity for a protein truncation mutation of sodium channel SCN8A in a patient with cerebellar atrophy, ataxia, and mental retardation. J Med Genet 2006; 43 (06) 527-530
• 45 Rauch A, Wieczorek D, Graf E. et al. Range of genetic mutations associated with severe non-syndromic sporadic intellectual disability: an exome sequencing study. Lancet 2012; 380 (9854): 1674-1682
• 46 Sprunger LK, Escayg A, Tallaksen-Greene S, Albin RL, Meisler MH. Dystonia associated with mutation of the neuronal sodium channel Scn8a and identification of the modifier locus Scnm1 on mouse chromosome 3. Hum Mol Genet 1999; 8 (03) 471-479
• 47 O'Brien JE, Drews VL, Jones JM, Dugas JC, Barres BA, Meisler MH. Rbfox proteins regulate alternative splicing of neuronal sodium channel SCN8A. Mol Cell Neurosci 2012; 49 (02) 120-126
• 48 Jones JM, Dionne L, Dell'Orco J. et al. Single amino acid deletion in transmembrane segment D4S6 of sodium channel Scn8a (Nav1.6) in a mouse mutant with a chronic movement disorder. Neurobiol Dis 2016; 89: 36-45
• 49 Ruggieri M, Praticò AD, Serra A. et al. Childhood neurofibromatosis type 2 (NF2) and related disorders: from bench to bedside and biologically targeted therapies. Acta Otorhinolaryngol Ital 2016; 36 (05) 345-367
• 50 Levin SI, Khaliq ZM, Aman TK. et al. Impaired motor function in mice with cell-specific knockout of sodium channel Scn8a (NaV1.6) in cerebellar purkinje neurons and granule cells. J Neurophysiol 2006; 96 (02) 785-793
• 51 Liu Y, Schubert J, Sonnenberg L. et al. Neuronal mechanisms of mutations in SCN8A causing epilepsy or intellectual disability. Brain 2019; 142 (02) 376-390
• 52 Butler KM, da Silva C, Alexander JJ, Hegde M, Escayg A. Diagnostic yield from 339 epilepsy patients screened on a clinical gene panel. Pediatr Neurol 2017; 77: 61-66
• 53 Butler KM, da Silva C, Shafir Y. et al. De novo and inherited SCN8A epilepsy mutations detected by gene panel analysis. Epilepsy Res 2017; 129: 17-25
• 54 Møller RS, Larsen LH, Johannesen KM. et al. Gene panel testing in epileptic encephalopathies and familial epilepsies. Mol Syndromol 2016; 7 (04) 210-219
• 55 Pratico AD, Falsaperla R, Ruggieri M, Corsello G, Pavone P. Prognostic challenges of SCN1A genetic mutations: report on two children with mild features. J Pediatr Neurol 2016; 14: 82-88
• 56 Connolly MB. Dravet syndrome: diagnosis and long-term course. Can J Neurol Sci 2016; 43 (Suppl. 03) S3-S8
• 57 Wei F, Yan LM, Su T. et al. Ion channel genes and epilepsy: functional alteration, pathogenic potential, and mechanism of epilepsy. Neurosci Bull 2017; 33 (04) 455-477
• 58 Lindy AS, Stosser MB, Butler E. et al. Diagnostic outcomes for genetic testing of 70 genes in 8565 patients with epilepsy and neurodevelopmental disorders. Epilepsia 2018; 59 (05) 1062-1071
• 59 Oates S, Tang S, Rosch R. et al. Incorporating epilepsy genetics into clinical practice: a 360°evaluation. NPJ Genom Med 2018; 3: 13
• 60 Singh D, Lau M, Ayers T. et al. De novo heterogeneous mutations in SCN2A and GRIN2A genes and seizures with ictal vocalizations. Clin Pediatr (Phila) 2016; 55 (09) 867-870
• 61 Parrini E, Marini C, Mei D. et al; Clinical Study Group. Diagnostic targeted resequencing in 349 patients with drug-resistant pediatric epilepsies identifies causative mutations in 30 different genes. Hum Mutat 2017; 38 (02) 216-225
• 62 Frasier CR, Wagnon JL, Bao YO. et al. Cardiac arrhythmia in a mouse model of sodium channel SCN8A epileptic encephalopathy. Proc Natl Acad Sci U S A 2016; 113 (45) 12838-12843
• 63 Bagnasco I, Dassi P, Blé R, Vigliano P. A relatively mild phenotype associated with mutation of SCN8A. Seizure 2018; 56: 47-49
• 64 Møller RS, Liebmann N, Larsen LHG. et al. Parental mosaicism in epilepsies due to alleged de novo variants. Epilepsia 2019; 60 (06) e63-e66
• 65 Wang J, Gao H, Bao X. et al. SCN8A mutations in Chinese patients with early onset epileptic encephalopathy and benign infantile seizures. BMC Med Genet 2017; 18 (01) 104
• 66 McNally MA, Johnson J, Huisman TA. et al. SCN8A epileptic encephalopathy: detection of fetal seizures guides multidisciplinary approach to diagnosis and treatment. Pediatr Neurol 2016; 64: 87-91
• 67 Trump N, McTague A, Brittain H. et al. Improving diagnosis and broadening the phenotypes in early-onset seizure and severe developmental delay disorders through gene panel analysis. J Med Genet 2016; 53 (05) 310-317
• 68 Falsaperla R, D'Angelo G, Praticò AD. et al. Ketogenic diet for infants with epilepsy: A literature review. Epilepsy Behav 2020; 112: 107361
• 69 Boerma RS, Braun KP, van den Broek MP. et al. Erratum to: remarkable phenytoin sensitivity in 4 children with SCN8A-related epilepsy: a molecular neuropharmacological approach. Neurotherapeutics 2016; 13 (01) 238
• 70 Boerma RS, Braun KP, van den Broek MP. et al. Remarkable phenytoin sensitivity in 4 children with SCN8A-related epilepsy: a molecular neuropharmacological approach. Neurotherapeutics 2016; 13 (01) 192-197
• 71 Pratico AD, Ruggieri M, Falsaperla R, Pavone P. A probable topiramate-induced limbs paraesthesia and rigid fingers flexion. Curr Drug Saf 2018; 13 (02) 131-136
• 72 Praticò AD, Pavone P, Scuderi MG. et al. Symptomatic hypocalcemia in an epileptic child treated with valproic acid plus lamotrigine: a case report. Cases J 2009; 2: 7394
• 73 Pratico AD, Longo L, Mansueto S. et al. Off-label use of drugs and adverse drug reactions in pediatric units: a prospective, multicenter study. Curr Drug Saf 2018; 13 (03) 200-207
• 74 Braakman HM, Verhoeven JS, Erasmus CE, Haaxma CA, Willemsen MH, Schelhaas HJ. Phenytoin as a last-resort treatment in SCN8A encephalopathy. Epilepsia Open 2017; 2 (03) 343-344
• 75 Baker EM, Thompson CH, Hawkins NA. et al. The novel sodium channel modulator GS-458967 (GS967) is an effective treatment in a mouse model of SCN8A encephalopathy. Epilepsia 2018; 59 (06) 1166-1176